UNICYCIVE THERAPEUTICS, INC. Increase (Decrease) in Prepaid Expense and Other Assets
UNICYCIVE THERAPEUTICS, INC. (UNCY) reported Increase (Decrease) in Prepaid Expense and Other Assets of $2.20 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets · last filed 2026-08-12
- UNICYCIVE THERAPEUTICS, INC. increase (decrease) in prepaid expense and other assets for the quarter ending 2026-06-30 was $936.00K.
- UNICYCIVE THERAPEUTICS, INC. increase (decrease) in prepaid expense and other assets for the quarter ending 2026-03-31 was $1.27M, a 48.93% decline year-over-year.
- UNICYCIVE THERAPEUTICS, INC. increase (decrease) in prepaid expense and other assets for the quarter ending 2025-12-31 was $98.00K.
- UNICYCIVE THERAPEUTICS, INC. increase (decrease) in prepaid expense and other assets for the quarter ending 2025-09-30 was $394.00K, a 88.36% decline year-over-year.
- UNICYCIVE THERAPEUTICS, INC. increase (decrease) in prepaid expense and other assets for fiscal 2025 was $2.88M, a 251.71% increase from fiscal 2024.
- UNICYCIVE THERAPEUTICS, INC. increase (decrease) in prepaid expense and other assets for fiscal 2024 was $820.00K, a 26.59% decline from fiscal 2023.
- UNICYCIVE THERAPEUTICS, INC. increase (decrease) in prepaid expense and other assets for fiscal 2023 was $1.12M.
- UNICYCIVE THERAPEUTICS, INC. increase (decrease) in prepaid expense and other assets for fiscal 2022 was -$62.00K.
| Period end | Increase (Decrease) in Prepaid Expense and Other Assets 3 month | Increase (Decrease) in Prepaid Expense and Other Assets 6 month | Increase (Decrease) in Prepaid Expense and Other Assets 9 month | Increase (Decrease) in Prepaid Expense and Other Assets 12 month |
|---|---|---|---|---|
| 2026-06-30 | $936.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-12 | $2.20M 10-Q · filed 2026-08-12 | $2.30M derived: sum of 3 quarters · filed 2026-08-12 | $2.69M derived: sum of 4 quarters · filed 2026-08-12 |
| 2026-03-31 | $1.27M 10-Q · filed 2026-05-12 | $1.36M derived: sum of 2 quarters · filed 2026-05-12 | $1.76M derived: sum of 3 quarters · filed 2026-05-12 | $1.67M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-12-31 | $98.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30 | $492.00K derived: sum of 2 quarters · filed 2026-03-30 | $403.00K derived: sum of 3 quarters · filed 2026-08-12 | $2.88M 10-K · filed 2026-03-30 |
| 2025-09-30 | $394.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | $305.00K derived: sum of 2 quarters · filed 2026-08-12 | $2.79M 10-Q · filed 2025-11-12 | $1.93M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-06-30 | -$89.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-12 | $2.39M 10-Q · filed 2026-08-12 | $1.53M derived: sum of 3 quarters · filed 2026-08-12 | $4.92M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-03-31 | $2.48M 10-Q · filed 2026-05-12 | $1.62M derived: sum of 2 quarters · filed 2026-05-12 | $5.01M derived: sum of 3 quarters · filed 2026-05-12 | $4.64M derived: sum of 4 quarters · filed 2026-05-12 |
| 2024-12-31 | -$857.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30 | $2.53M derived: sum of 2 quarters · filed 2026-03-30 | $2.16M derived: sum of 3 quarters · filed 2026-03-30 | $820.00K 10-K · filed 2026-03-30 |
| 2024-09-30 | $3.39M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | $3.02M derived: sum of 2 quarters · filed 2025-11-12 | $1.68M 10-Q · filed 2025-11-12 | $910.00K derived: sum of 4 quarters · filed 2025-11-12 |
| 2024-06-30 | -$365.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-14 | -$1.71M 10-Q · filed 2025-08-14 | -$2.48M derived: sum of 3 quarters · filed 2025-08-14 | -$1.36M derived: sum of 4 quarters · filed 2025-08-14 |
| 2024-03-31 | -$1.34M 10-Q · filed 2025-05-14 | -$2.11M derived: sum of 2 quarters · filed 2025-05-14 | -$998.00K derived: sum of 3 quarters · filed 2025-05-14 | $111.00K derived: sum of 4 quarters · filed 2025-05-14 |
| 2023-12-31 | -$767.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-31 | $346.00K derived: sum of 2 quarters · filed 2025-03-31 | $1.46M derived: sum of 3 quarters · filed 2025-03-31 | $1.12M 10-K · filed 2025-03-31 |
| 2023-09-30 | $1.11M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-13 | $2.22M derived: sum of 2 quarters · filed 2024-11-13 | $1.88M 10-Q · filed 2024-11-13 | $2.22M derived: sum of 4 quarters · filed 2024-11-13 |
| 2023-06-30 | $1.11M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-14 | $771.00K 10-Q · filed 2024-08-14 | $1.11M derived: sum of 3 quarters · filed 2024-08-14 | |
| 2023-03-31 | -$338.00K 10-Q · filed 2024-05-13 | -$3.00K derived: sum of 2 quarters · filed 2024-05-13 | ||
| 2022-12-31 | $335.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-28 | -$62.00K 10-K · filed 2024-03-28 | ||
| 2022-09-30 | -$397.00K 10-Q · filed 2023-11-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| TuHURA Biosciences, Inc./NV (HURA) | United States | $0.134B | -4.88 |
| NRX Pharmaceuticals, Inc. (NRXP) | United States | $0.131B | -6.31 |
| Curanex Pharmaceuticals Inc (CURX) | United States | $0.138B | |
| MEDICINOVA INC (MNOV) | United States | $0.130B | -6.04 |
| Atrium Therapeutics, Inc. (RNA) | United States | $0.140B | |
| Korro Bio, Inc. (KRRO) | United States | $0.141B | -1.81 |
| IMMUNIC, INC. (IMUX) | United States | $0.127B | -1.88 |
| SPRUCE BIOSCIENCES, INC. (SPRB) | United States | $0.142B | -2.89 |
| INOVIO PHARMACEUTICALS, INC. (INO) | United States | $0.125B | -1.35 |
| Corbus Pharmaceuticals Holdings, Inc. (CRBP) | United States | $0.144B | -1.72 |